Up-dosing with bilastine results in improved effectiveness in cold contact urticaria

K. Krause, A. Spohr, T. Zuberbier, M. K. Church & M. Maurer

Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany

To cite this article: Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–928.

Abstract

Background: Cold contact urticaria (CCU) is characterized by itchy wheal and flare responses due to the release of histamine and other pro-inflammatory mediators after exposure to cold. The treatment of choice is nonsedating antihistamines, dosages of which may be increased up to fourfold if standard doses are ineffective. Here, we assess the effects of a standard 20 mg dose and up-dosing to 40 and 80 mg of bilastine in reducing the symptoms of CCU and inflammatory mediator release following cold challenge.

Methods: Twenty patients with CCU were included in this randomized, crossover, double-blind, placebo-controlled 12-week study. They received placebo, 20, 40 or 80 mg of bilastine daily each for 7 days with 14-day washout periods. The primary readout was change in critical temperature thresholds (CTT). Secondary readouts were changes in pruritus, levels of histamine IL-6, IL-8 and TNF-α collected by skin microdialysis and safety and tolerability of bilastine.

Results: Bilastine 20 mg was highly effective (P < 0.0001) in reducing CTT. Up-dosing to 80 mg significantly (P < 0.04) increased its effectiveness. At this dose, 19 of 20 (95%) patients responded to treatment, with 12 of 20 (60%) becoming symptom free. Only one patient was refractory to treatment. Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine. Bilastine treatment was well tolerated without evidence of increased sedation with dose escalation.

Conclusions: Bilastine was effective in reducing the symptoms of patients with CCU. Increased efficacy of bilastine with fourfold up-dosing was without sedation and supports urticaria treatment guidelines.

The current EAACI/GA²LEN/EDF/WAO guidelines for the treatment for urticaria (1) recommend first-line use of new-generation, nonsedating H1-antihistamines and provide an option to increase the dosage up to fourfold if standard doses are not effective. In this study, we tested the validity of this recommendation by comparing the effectiveness of the H1-antihistamine, bilastine, at the manufacturer’s recommended standard dose with up-dosing to four times the standard dose.

Bilastine is a new H1-antihistamine approved recently for the symptomatic treatment for allergic rhinoconjunctivitis and urticaria. In vitro studies (2) have shown bilastine to have moderate-to-high affinity and potent activity at the histamine H1-receptor while having negligible affinity or effects at 30 other receptors. A review of preliminary clinical data (3) has shown that bilastine is rapidly and effectively absorbed, undergoes negligible metabolism (4) and is a substrate for P-glycoprotein (5), which limits its passage across the blood–brain barrier. At the recommended dose of 20 mg, bilastine is nonsedative, does not enhance the effects of
alcohol or lorazepam, does not impair actual driving tests (6) and shows no cardiotoxicity (7, 8). Bilastine’s long duration of action, efficacy and freedom from central nervous system sedative effects make it a potentially attractive option for use in this clinical situation.

The model used to study bilastine was cold contact urticaria (CCU), a rare but severe and potentially lethal condition. It is characterized by itchy wheal and flare responses due to the release of histamine and other pro-inflammatory mast cell mediators such as tumour necrosis factor-α (TNF-α), prostaglandin D₂ (PGD₂) and platelet-activating factor (PAF) following exposure of the skin to the cold (9). Life-threatening angioedema and anaphylaxis may occur after ingestion of cold foods and systemic exposure to cold, respectively (9, 10). Because of its potential severity, it is essential that CCU is treated with the most effective therapeutic agents. In addition to the recommended standard treatment with second-generation antihistamines, the use of leukotriene antagonists, ciclosporin, antibiotics and anti-IgE therapy has been reported for therapy-refractive cases (1).

Recent data have shown that updosing of antihistamines is significantly more effective in reducing symptoms in CCU than standard-dose treatment (11, 12). However, there is still a need for identifying the effects of high-dose antihistamines compared with standard doses on mast cell mediator release, such as histamine and cytokines, in urticaria patients.

It has recently become possible to assess the severity of cold contact urticaria by measuring critical temperature thresholds (CTT) for the production of wheal responses on discrete areas of the skin using a Peltier effect-based electronic device (9, 12–14). This method has been previously compared with the ice cube challenge tests and found to be more suitable for performing standardized threshold testing (13).

With this study, we aimed at evaluating dose-dependent antihistaminic effects of bilastine on symptom development (e.g. temperature thresholds) and mast cell mediator release in CCU. The primary objective of the present cold urticaria provocation study was to assess changes in CTT for production of wheal responses in the skin following treatment with bilastine at 20, 40 and 80 mg daily for seven days. The secondary objectives were to evaluate the safety and tolerability and to use dermal microdialysis to assess the potential anti-inflammatory effects of bilastine in reducing histamine and cytokine release following cold provocations.

**Methods**

This was a prospective, randomized, double-blind, placebo-controlled, triple cross-over study to assess the efficacy, mechanisms and safety of treatment with 20 mg, 40 mg, 80 mg of bilastine and placebo administered once daily for 7 days in patients with cold contact urticaria. The design of the study is shown in Fig. 1. A total of 20 patients (seven men and 13 women, mean age 45 years, range 22–68 years) with a confirmed diagnosis of CCU made at least 6 weeks before screening were included in this study. The group size was estimated using a power of 80% (t-test) with a two-sided significance level of 5% and a medium effect of 1.2 SD. The patients were drawn from the outpatient population at the urticaria specialty clinic of the Allergie-Centrum-Charité-Universitätsmedizin and associated dermatological institutions in Berlin, Germany.

The study was approved by the ethics committee of the State of Berlin (EudraCT number: 2010-019344-39) and was conducted according to the Declaration of Helsinki and the ‘Good Clinical Practice, Standard Operating Procedures of the Allergy Centre Charité and the Coordination Centre for Clinical Studies of the Charité-Universitätsmedizin Berlin’. Its clinicaltrials.gov identifier number is NCT 01271075. Recruitment began in December 2010 and the study completed in August 2011. All participants gave signed informed consent at the beginning of the study.

**Study design**

At the screening visit, information about concomitant disease and previous medication use was collected and the patients were subjected to a general physical examination, laboratory blood analyses and an electrocardiogram. A cold provocation test was performed, and patients who exhibited a positive reaction comprising wheal and itching within 10 min of cold provocation with Temp Test 3.0° (emoSystems, Berlin, Germany) at 4°C were eligible for the study provided they were not excluded for other reasons.

---

**Figure 1** Study design: This was a double-blind, placebo-controlled, triple cross-over study of 20 patients with cold contact urticaria (CCU) treated daily for 7 days with bilastine (B) 20, 40 and 80 mg and placebo. Measurements were taken of critical temperature threshold (CTT) and skin microdialysis performed to assess histamine and cytokine generation.
The exclusion criteria were a documented or suspected history of allergic disease; any acute or chronic disease; symptoms of a clinically significant illness, especially liver or kidney disease; a history of hypersensitivity to the study drug(s) or formulation ingredients; epilepsy or other seizure conditions; hereditary galactose intolerance; lactase deficiency or glucose-galactose malabsorption; drug abuse or excessive use of alcohol or tobacco. Pregnant or nursing women were also excluded. Oral antihistamines, antidepressants, antipsychotics or corticosteroids, aluminium- and magnesium-containing antacids, ketoconazole and erythromycin, as well as topically applied antihistamines, corticosteroids or mast cell stabilizers were forbidden for 2 weeks prior to testing. Further, participants were forbidden to consume citrus fruits for 24 h before or during study days due to their possible effects on the bioavailability of bilastine (3). All women of childbearing potential had to use an effective method of contraception during the study and 3 months thereafter.

After a washout period of 14–28 days, patients were assessed for critical temperature threshold (CTT) using the Temp Test 3.0®. Patients without a positive reaction at threshold testing discontinued their participation; these subjects were replaced. Microdialysis was performed to determine the levels of histamine, IL-6, IL-8 and TNF-α in the dermis before cold provocation and 0–20 and 20–60 min (histamine) and 2–3 h (cytokines) afterwards.

Medication, dosage and administration

Identical tablets containing either 20 mg bilastine or placebo were manufactured by FAES FARMA S.A. (Bilbao, Spain). Each morning for seven days before treatment visits, patients took four tablets, a mixture of bilastine 20 mg and placebo tablets, to achieve the required dose. To facilitate randomization, tablets were packaged in aluminium strips, each containing four tablets for each morning and labelled with patient randomization number and directions for use. Patients were instructed to take their medication at least 1 h after consumption of food and that fruit juice drinks should be avoided.

Study readouts

Primary readout

Critical temperature threshold (CTT), defined as the highest temperature that produces a positive wheal response (11), was determined using a Temp Test® 3.0, a Peltier effect-based electronic device designed specifically for diagnosing and monitoring CCU symptoms (9). The temperature head of this device, which was placed directly on the volar surface of the forearm, consists of twelve elements, each 10 mm in diameter, arranged in two parallel rows. The device was set to deliver temperatures of 26, 24, 22, 20, 18, 16, 14, 12, 10, 8, 6 and 4°C (each ± 0.1°C) to the skin for a constant period of 5 min. A positive response is the development of a wheal, either confluent or nonconfluent, and itching within 5 min of removing the Temp Test 3.0®.

Secondary readouts

The severities of itching and burning of the cold-induced lesions were assessed 10 min after the end of cold provocation and recorded as: 0 absent, 1 mild, 2 moderate and 3 severe. The determination of pruritus and burning was performed at a single 4°C provocation site separate from that of the determination of CTT.

Microdialysis was used at visit V2 (baseline), visit V3 and visit V6 to determine the release of histamine and the generation of cytokines IL-6, IL-8 and TNF-α. Two linear cutaneous microdialysis membranes (3000 kDa molecular mass cut-off) were inserted into the volar surface of each forearm of the volunteers, under topical local anaesthesia (EMLA cream; Astra Pharmaceuticals, Kings Langley, UK) as previously described (15). Each membrane ran for a length of 20 mm, at a depth of approximately 0.7 mm. A 1-h period was allowed for recovery from local anaesthesia and trauma before the start of perfusion with Ringer’s solution at a rate of 3 µl/min using a microinfusion pump. To assess baseline mediator levels, dialysate was collected from both probes for 30 min before cold provocation (4°C for 5 min) of the skin above one fibre. The other fibre served as unprovoked control. Dialysate was collected for the determination of histamine during two time periods, 0–20 and 20–60 min after the beginning of provocation. Further collections were made between 2 and 3 h for the determination of cytokines. Dialysate samples were collected in vials and stored at −80°C before analysis. Histamine was measured by Histareader™ (REFlab, Copenhagen, Denmark). Cytokines were measured by FlowCytomix™ Pro 2.4 (eBioscience, San Diego, CA, USA).

Adverse events and follow-up

Patients were questioned at each visit about the occurrence of adverse events during the previous treatment period and washout phase, and a general physical examination, ECG and laboratory blood analyses were performed at the final visit. As this was a study involving a licensed and widely used H1-antihistamine, no formal follow-up was undertaken.

Statistics

The results for critical temperature thresholds and pruritus are expressed as median (with 75% confidence limits) and the significance of differences is calculated using Wilcoxon’s non-parametric test. The overall chi-square differences between treatments were calculated using Friedman’s nonparametric test. The significance values for the numbers of individual
patients responding or not responding to treatments were calculated using Fisher’s exact test. The results for histamine and cytokines are expressed as mean/C6/ standard error of mean (SEM) and the significance of differences is tested using Student’s t-test for paired data.

Results

Critical temperature thresholds

Effectiveness of bilastine at standard dosing

The median CTT (with 75% confidence limits) for the placebo treatment was 18°C (8.5–22°C). In addition, only one patient was symptom free, that is, there was no evidence of a whealing response, at a provocation temperature of 4°C, the minimal testing temperature.

Following daily dosing for seven days with a standard dose of 20 mg bilastine, the median CTT value was 6°C (0–14°C), highly significantly different from the placebo treatment (P < 0.0001, Wilcoxon’s T test) (Fig. 2, Table 1). Also, 7 (35%) patients became symptom free (P = 0.044 vs placebo, Fisher’s exact test) at this dose.

Up-dosing with bilastine

The median CTT values following seven-day treatment with 40 mg and 80 mg bilastine were both below the minimal testing temperature of 4°C. The respective values of 4°C (11 to <4°C) and 4°C (5.5 to <4°C) were highly significantly (P < 0.0001, Wilcoxon’s T test) different from those of placebo treatment (Fig. 2, Table 1). Furthermore, the median CTT with 80 mg bilastine was significantly lower than both that of 20 mg (P = 0.003) and 40 mg (P = 0.04), illustrating the benefit of up-dosing. In addition, 11 (55%) and 12 (60%) patients, respectively, became symptom free (P = 0.0012 and P = 0.0004 vs placebo, Fisher’s exact test) on 40 and 80 mg bilastine. There were no significant differences between drug doses in the number of patients becoming symptom free.

The Friedman’s chi-square test value of 41.836 indicates a highly significant (P < 0.0001, test) treatment effect of bilastine, taking all doses into consideration.

Pruritus

The median pruritus score (with 75% confidence limits) for the placebo treatment was 2.0 (1.25–3.0), and three patients reported no itch (Fig. 3). Following treatment with the standard bilastine dose of 20 mg daily, the median pruritus score was 0 (0–1) (P = 0.001 vs placebo, Wilcoxon’s T test), with 13 of the 20 patients reporting no itch (P = 0.003 vs placebo, Fisher’s exact test).

Following up-dosing with 40 mg and 80 mg bilastine, the median pruritus scores were 0 (0–1) and 0.5 (0–1). These were significantly different from placebo (P = 0.001 and P < 0.003, Wilcoxon’s T test). In addition, 12 and 10 patients on 40 and 80 mg bilastine, respectively, reported no pruritus (P = 0.007 and P = 0.041 versus placebo, Fisher’s exact test). There were no significant differences between doses.

| Table 1 Individual response of critical temperature thresholds (CTT) to bilastine treatment |
|------------------------------------------|-----|-----|-----|-----|-----|
| Patient number | Baseline | Placebo | Bilastine 20 mg | Bilastine 40 mg | Bilastine 80 mg |
|----------------|---------|--------|-----------------|-----------------|-----------------|
| 1              | 20      | 16     | 14              | 12              | 10              |
| 2              | 20      | 22     | 14              | 10              | 12              |
| 3              | 14      | 4      | 0               | 0               | 0               |
| 4              | 12      | 22     | 6               | 0               | 0               |
| 5              | 22      | 24     | 8               | 16              | 0               |
| 6              | 12      | 18     | 4               | 0               | 4               |
| 7              | 27      | 10     | 0               | 0               | 0               |
| 8              | 12      | 12     | 6               | 0               | 0               |
| 9              | 24      | 27     | 24              | 22              | 22              |
| 10             | 12      | 8      | 0               | 0               | 0               |
| 11             | 27      | 27     | 10              | 12              | 4               |
| 12             | 22      | 20     | 8               | 0               | 0               |
| 13             | 16      | 14     | 0               | 6               | 0               |
| 14             | 18      | 22     | 16              | 0               | 4               |
| 15             | 4       | 0      | 0               | 0               | 0               |
| 16             | 22      | 24     | 14              | 10              | 6               |
| 17             | 10      | 6      | 0               | 6               | 0               |
| 18             | 22      | 18     | 6               | 16              | 8               |
| 19             | 20      | 18     | 8               | 0               | 0               |
| 20             | 10      | 8      | 0               | 0               | 0               |
| Median         | 19      | 18     | 6               | 0               | 0               |
| 75% Limit      | 22      | 22     | 13              | 11              | 5.5             |
| 25% Limit      | 12      | 8.5    | 0               | 0               | 0               |

Figure 2 Critical temperature thresholds for the production of wheals following cold provocation. The horizontal lines indicate medians. The levels of significance values are for differences in the median critical temperature thresholds calculated using Wilcoxon’s nonparametric test.
The Friedman’s chi-square test value of 26.650 indicates a highly significant ($P < 0.0001$, test) treatment effect of bilastine on pruritus.

Five patients in the placebo group reported a burning sensation following cold provocation, one at severity level 3 and two each at levels 2 and 1. Following administration of 20 mg bilastine, two patients reported burning, one at level 2 and one at level 1. With 40 mg bilastine, only one patient reported burning at level 1. With 80 mg bilastine, three patients reported burning, one at level 2 and two at level 1. These numbers were too low for meaningful statistical analysis.

Levels of histamine and cytokines

**Histamine**

Histamine recovered by microdialysis from the unprovoked skin of untreated patients during 20 min was $19.2 \pm 1.8$ ng/ml (mean $\pm$ SEM). In the 0–20 min collection period following provocation, the concentration of histamine in the dialysate was $108.0 \pm 18.1$ ng/ml (Fig. 4A). This 5.6-fold increase was highly significant ($P < 0.0001$). The 5.7- and 6.4-fold increases of histamine in provoked skin compared with unprovoked skin in patients treated with bilastine at a standard 20 mg dose or up-dosed with 80 mg were not significantly different from those of untreated patients.

In untreated patients, the mean histamine level during the 20–60 min collection period in provoked skin of $35.7 \pm 6.2$ ng/ml was significantly ($P = 0.005$) higher than that in unprovoked skin of $20.9 \pm 2.1$ ng/ml (Fig. 4B). Following treatment with 20 or 80 mg bilastine, the mean histamine levels in provoked skin of $23.7 \pm 3.2$ and $23.5 \pm 3.1$ ng/ml were significantly ($P = 0.02$ and $P = 0.013$, respectively) lower than that in skin of untreated patients.

**Cytokines**

In untreated patients, cold provocation caused a small but not statistically significant increase in levels of IL-6 recovered by microdialysis (Fig. 5A). In contrast, cold provocation caused 60% increase in levels of IL-8 ($P = 0.002$) (Fig. 5B). Detectable baseline levels of TNF-$\alpha$ were found in only seven of the 20 patients and in only two of these did provocation lead to small increases.

Treatment of patients with a standard dose of 20 mg bilastine did not cause a significant reduction in either IL-6 or IL-8. However, up-dosing with 80 mg bilastine daily for 7 days caused a 34% ($P = 0.026$) reduction in IL-6 and a 37%
reduction in IL-8 compared with when the patients were untreated.

Adverse events

No severe adverse events or suspected unexpected serious adverse reactions occurred during this study. No volunteer withdrew from the study before its completion. A total of 17 adverse events (AEs) were reported. One patient reported sedation on one study day with 40 mg bilastine, one dizziness with 40 mg bilastine and two others headache alone (1 with 20 mg bilastine and 2 with 40 mg bilastine). However, these patients did not report these complaints consistently and not when taking the higher dose of 80 mg bilastine. Thus, these AEs are not considered to be drug-related. Other AEs, which were also probably not drug-related, included: exanthema (one patient, 40 mg bilastine), dyspnoea (one patient, placebo), bronchitis/laryngitis (three patients, 80 mg bilastine), upper respiratory tract infection (one patient, 20 mg bilastine), gastric pain (two patients, 20 mg bilastine; two patients, 40 mg bilastine; one patient, 80 mg bilastine) and constipation (one patient, 20 mg bilastine). There were no reported adverse responses after the end of the study.

Discussion

This study showed that bilastine given daily for seven days before provocation is an effective H1-antihistamine in reducing the symptoms of cold contact urticaria, including wheal formation and pruritus. Increasing the dose of bilastine from 20 mg through 40 mg to 80 mg daily increased its effectiveness. Sedation was reported by only one patient with 40 mg bilastine. Histamine release was unaffected during the early phase of the response (0–20 min). However, levels of histamine collected during the 20- to 60-min period and IL-6 and IL-8 collected during the 2- to 3-hour period were significantly reduced, particularly when patients were treated with bilastine 80 mg.

The primary read-out in this study was assessment of critical temperature thresholds (CTT) which correlate the severity and activity of CCU (9, 14). When administered at the standard dose of 20 mg, bilastine was an effective inhibitor of CCU symptoms causing a reduction in the median CTT from 19°C to 6°C (68% reduction) and causing 35% of the patients to be symptom free with the lowest provocation temperature of 4°C. Increasing the dose of bilastine to 40 mg and then to 80 mg daily in line with the current EAACI/GA2LEN/EDF/WAO guidelines for the treatment for urticaria (1) significantly increased the effectiveness of the drug. With 80 mg bilastine, the median CTT was reduced to <4°C and 60% patients became symptom free.

In the first of three other studies using CTT as an output measure, desloratadine at 5 mg daily for one week reduced the mean CTT from 20.5°C to 15.2°C (26% reduction) with 7 of 30 (23%) patients becoming symptom free (11). Increasing the dose to 20 mg reduced the mean CTT to 11°C (47% reduction), with 50% of the patients becoming symptom free. In the second study, desloratadine at 5 mg daily for two weeks resulted in a reduction in mean CTT 22°C to 19°C (14% reduction), with no patients becoming symptom free (12). Increasing the dose to 20 mg further reduced the CTT to 12°C (45% reduction), with 5 of 15 (33%) patients becoming symptom free. In the third study, rupatadine at 20 mg daily for one week, twice the standard dose, reduced the median CTT from 18°C to 6°C (57% reduction), with 11 of 20 (52%) patients becoming symptom free (16).
Cold provocation produced a marked pruritic response in all but two patients during the period in which they were taking placebo. This response was significantly inhibited by bilastine at all doses. Because pruritus was assessed on a short four-point Likert scale, differences between doses were not apparent.

One outstanding feature of bilastine pharmacology is its interaction with transporter systems, including P-glycoprotein, which limit its penetration into the brain (5, 17). In addition, clinical objective psychomotor tests and subjective assessment of drowsiness indicate the absence of effects of bilastine on the central nervous system. These tests also show a lack of interaction of bilastine with lorazepam and alcohol (3, 18). The lack of sedation caused by bilastine, even with dose escalation, was highlighted in the present study by the fact that there was only one report of drowsiness by a single patient with 40 mg bilastine.

In untreated patients, there was a 5.6-fold increase in the concentration of histamine recovered by microdialysis during the first 20 minutes after cold provocation. This was not inhibited by bilastine at any dose. Although inhibition of histamine release from mast cells by H1-antihistamines, including bilastine, has been demonstrated often in vitro, the concentrations used are invariably higher than those usually reached during clinical therapy (19–23). Our observation that bilastine did not inhibit histamine release in vivo is consistent with previous reports using skin chambers or microdialysis that H1-antihistamines do not reduce histamine released in the skin following provocation with allergen or codeine (24–26).

In the microdialysis sample collected from untreated patients during the 20- to 60-min period, there was a small but significantly higher concentration of histamine in the provoked site compared with the nonprovoked site. Although the mechanism for this is not clear, it may be speculated that this is due to an influx and activation of basophils as is seen in late-phase responses to allergen (27–29) even though the cellular infiltrates in CCU are said to be ‘scanty’ due to the fleeting nature of these lesions (30).

The presence of an inflammatory response is supported by the observation of significant levels of IL-6 and IL-8, initially caused by the insertion of the microdialysis fibres (15). While allergen challenge significantly enhances the levels of both IL-6 and IL-8 (15), cold provocation caused a small but significant rise in IL-8 and a small, but not statistically significant, rise in IL-6. This is consistent with the observation of a small up-regulation in CCU of cytokines observed by histology (31). Both IL-6 and IL-8 levels were significantly reduced by 80 mg but not 20 mg bilastine, again showing the advantage of up-dosing.

This study has shown that bilastine is an effective H1-antihistamine in reducing the symptoms of CCU when used in standard doses. Furthermore, up-dosing to 80 mg daily supports the urticaria treatment guidelines by showing excellent safety and no sedation while increasing its efficacy and anti-inflammatory properties.

Acknowledgments
We thank Hesna Gözlükaya and Marina Frömming for excellent technical assistance and Jodie Urcioli for proof-reading the manuscript.

Author contributions
Karoline Krause, Torsten Zuberbier, Martin Church and Marcus Maurer were responsible for experimental design, statistics and preparation of the manuscript. Karoline Krause and Adrian Spohr were responsible for patient recruitment, practical aspects and assistance with preparation of the manuscript.

Funding
The study was funded by an unrestricted grant from FAES FARMA, Bilbao, Spain.

Conflicts of interest
Karoline Krause has received honoraria from Dr. Pfleger GmbH and Novartis. Torsten Zuberbier has been a speaker or consultant for FAES Pharma, Menarini, MSD, Sanofi-Aventis and Uriach. Martin Church has been a speaker or consultant for Almirall, FAES Pharma, Menarini, MSD, UCB Pharma, Sanofi-Aventis and Uriach. Marcus Maurer has been a speaker or consultant for Almirall, FAES Pharma, Genentech, Menarini, MSD, Novartis, UCB Pharma, Sanofi-Aventis and Uriach. Adrian Spohr declares no conflict of interest.

References
1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter CG, Church MK, Gimenez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427–1443.
2. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371–384.
3. Church MK. Safety and efficacy of bilastine: a new H1(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011;10:779–793.
4. Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol 2012;35 (Suppl 1):18–24.
5. Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E et al. Interactions of bilastine, a new oral H(1) antihistamine, with human transporter systems. Drug Chem Toxicol 2012;35(Suppl 1):8–17.
6. Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011;25:1517–1523.
7. Graff C, Struijk JJ, Kantiers JK, Andersen MP, Toft E, Tyl B. Effects of bilastine on
Bilastine in cold contact urticaria

Krause et al.

T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig 2012;32:339–351.

8. Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbold E et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012;52:893–903.

9. Siebenhaar F, Weller K, Mlynek A, Magerl M, Altrichter S, Dos Vieira SR et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 2007;32:241–245.

10. Zubervier T, Asero R, Bindslev-Jensen C, Walter CG, Church MK, Gimenez-Arnau A et al. EAAC1/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417–1426.

11. Siebenhaar F, Degener F, Zubervier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123:672–679.

12. Magerl M, Pisarevskaia D, Staubach P, Martus P, Church MK, Maurer M. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H1-antihistamine dose escalation. Br J Dermatol 2012;166:1095–1099.

13. Siebenhaar F, Staubach P, Metz M, Magerl M, Jung J, Maurer M. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 2004;114:1224–1225.

14. Mlynek A, Magerl M, Siebenhaar F, Weller K, Dos Vieira SR, Zubervier T et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol 2010;162:198–200.

15. Clough GF, Jackson CL, Lee JJ, Jamal SC, Church MK. What can microdialysis tell us about the temporal and spatial generation of cytokines in allergen-induced responses in human skin in vivo? J Invest Dermatol 2007;127:2799–2806.

16. Metz M, Scholz E, Ferran M, Izquierdo I, Gimenez-Arnau A, Maurer M. Rupatadine and its effects on symptom control, stimulation and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104:86–92.

17. Lucero ML, Patterson AB. Whole-body tissue distribution of total radioactivity in rats after oral administration of [(14)C]-bilastine. Drug Chem Toxicol 2012;35(Suppl 1):1–7.

18. Montoro J, Mullol J, Davila I, Ferrer M, Sastre J, Bartra J et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol 2011;21(Suppl 3):9–15.

19. Okayama Y, Benyon RC, Lowman MA, Church MK. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil and skin. Allergy 1994;49:246–253.

20. Church MK, Collinson AD, Okayama Y. H1-receptor antagonists: anti-allergic effects in vitro. In: Simons FER, editor. Histamine and H1-Receptor Antagonists in Allergic Disease. New York: Marcel Dekker, 1996:117–145.

21. Baroody FM, Nackerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000;55(Suppl 44):17–27.

22. Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol 2009;129:2723–2726.

23. Bachert C, Kuna P, Zubervier T, Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010;65(Suppl 93):1–13.

24. Charlesworth EN, Massey WA, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992;262:964–970.

25. Perzanowska M, Malhotra D, Skinner SP, Rioux JP, Bewley AP, Petersen LJ et al. The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res 1996;45:486–490.

26. Roquet A, Raud J, Hallden G, Hagemann M, Hed J, Hansson LO et al. Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy 1995;50:414–420.

27. Kleinjan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ. Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000;106:677–686.

28. Macfarlane AJ, Kon OM, Smith SJ, Ziebeckoglu K, Khan LN, Barata LT et al. Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol 2000;105(1 Pt 1):99–107.

29. Bacon AS, Abluwalil P, Irani AA, Schwartz LB, Holgate ST, Church MK et al. Tear and conjunctival changes during the allergen-induced early and late phase responses. J Allergy Clin Immunol 2000;106(5 Pt 1):948–954.

30. Haas N, Toppe E, Henz BM. Microscopic morphology of different types of urticaria. Arch Dermatol 1998;134:41–46.

31. Hermes B, Prochazka AK, Haas N, Jurgovsk y K, Sticherling M, Henz BM. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999;103(2 Pt 1):307–314.